Skip to main content

TE VA 7630 (Imatinib Mesylate 400 mg)

Pill with imprint TE VA 7630 is Brown, Capsule-shape and has been identified as Imatinib Mesylate 400 mg. It is supplied by Teva Pharmaceuticals USA, Inc.

Imatinib is used in the treatment of chronic myelogenous leukemia; dermatofibrosarcoma protuberans; acute lymphoblastic leukemia; chronic eosinophilic leukemia; gastrointestinal stromal tumor and belongs to the drug class BCR-ABL tyrosine kinase inhibitors. There is positive evidence of human fetal risk during pregnancy. Imatinib 400 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for TE VA 7630

Imatinib mesylate 400 mg TE VA 7630

Imatinib Mesylate

TE VA 7630
400 mg
19.00 mm
Prescription only
Drug Class
BCR-ABL tyrosine kinase inhibitors
Pregnancy Category
D - Positive evidence of risk
CSA Schedule
Not a controlled drug
Labeler / Supplier
Teva Pharmaceuticals USA, Inc.
National Drug Code (NDC)
Inactive Ingredients
silicon dioxide, croscarmellose sodium, FD&C Yellow No. 6, hypromellose 2910 (6 mPa.s), ferric oxide yellow, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium stearyl fumarate, magnesium silicate, titanium dioxide

Note: Inactive ingredients may vary.

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.